Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification

Nature Clinical Practice Oncology

Volumn 4, Issue 5, 2007, Pages 295-304

  Polkinghorn, William R ^a   Tarbell, Nancy J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; NEUROTROPHIN 3 RECEPTOR; PROTEIN PATCHED 1; SONIC HEDGEHOG PROTEIN; WNT1 PROTEIN; TUMOR MARKER;

ADJUVANT THERAPY; ANAPLASTIC CARCINOMA; ANEUPLOIDY; BRAIN RADIATION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME 17P; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYTOGENETICS; DISEASE FREE SURVIVAL; GRANULE CELL; HISTOPATHOLOGY; HUMAN; MEDULLOBLASTOMA; METASTASIS; MONOTHERAPY; NEURAL STEM CELL; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; CELL TRANSFORMATION; CEREBELLUM TUMOR; CHILD; GENETICS; PATHOLOGY; SURVIVAL;

CELL TRANSFORMATION, NEOPLASTIC; CEREBELLAR NEOPLASMS; CHILD; CYTOGENETICS; HUMANS; MEDULLOBLASTOMA; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247862359     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0794     Document Type: Review

References (95)

1. Gurney JG et al. (1996) Trends in cancer incidence among children in the US. Cancer 78: 532-541
2. McNeil DE et al. (2002) Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 39: 190-194
3. Gurney JG and Kadan-Lottick N (2001) Brain and other central nervous system tumors: Rates, trends, and epidemiology. Curr Opin Oncol 13: 160-166
4. Halperin EC et al. (2005) Pediatric Radiation Oncology. Philadelphia: Lippincott Williams and Wilkins
5. Pomeroy SL et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 41 436-442
6. Fouladi M et al. (1999) Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 17: 3234-323
7. Bailey P and Cushing H (1925) Medulloblastoma cerebelli: A common type of midcerebellar glioma of childhood. Arch Neurol Psychiatry 14 192-224
8. Cushing H (1930) Experiences with the cerebellar medulloblastomas: A critical review. Acta Pathol Microbiol Scand 1: 1-86
9. Bloom HJ et al. (1969) The treatment and prognosis of medulloblastoma in children: A study of 82 verified cases. Am J Roentgenol Radium Ther Nucl Med 105: 43-62
10. St Clair WH et al. (2004) Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 58: 727-734
11. Wang VY and Zoghbi HY (2001) Genetic regulation of cerebellar development. Nat Rev Neurosci 2: 484-491
12. Fogarty MP et al. (2005) Morphing into cancer: The role of developmental signaling pathways in brain tumor formation. J Neurobiol 64: 458-475
13. Marino S (2005) Medulloblastoma: Developmental mechanisms out of control. Trends Mol Med 11: 17-22
14. Knoepfler PS and Kenney AM (2006) Neural precursor cycling at sonic speed: N-Myc pedals, GSK-3 brakes. Cell Cycle 5: 47-52
15. Wechsler-Reya RJ and Scott MP (1999) Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 22 103-114
16. Dellovade T et al. (2006) The hedgehog pathway and neurological disorders. Annu Rev Neurosci 29: 539-563
17. Kimura H et al. (2005) Gli1 is important for medulloblastoma formation in Ptc1+/- mice. Oncogene 24: 4026-4036
18. Kenney AM et al. (2003) Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 130: 15-28
19. Oliver TG et al. (2003) Transcriptional profiling of the Sonic hedgehog response: A critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci USA 100: 7331-7336
20. Rao G et al. (2004) Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23: 6156-6162
21. Browd SR et al. (2006) N-myc can substitute for insulinlike growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res 66: 2666-2672
22. Zurawel RH et al. (2000) Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 27: 44-51
23. Hallahan AR et al. (2004) The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64: 7794-7800
24. Thompson MC et al. (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924-1931
25. Baeza N et al. (2003) AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 22: 632-636
26. Eberhart CG et al. (2000) Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 59 333-337
27. Huang H et al. (2000) APC mutations in sporadic medulloblastomas. Am J Pathol 156: 433-437
28. Zurawel RH et al. (1998) Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 58: 896-899
29. Holcomb VB et al. (2006) Ku80 and p53 suppress medulloblastoma that arise independent of Rag-1-induced DSBs. Oncogene 25: 7159-7165
30. Yan CT et al. (2006) XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient mice. Proc Natl Acad Sci USA 103: 7378-7383
31. Lee Y and McKinnon PJ (2002) DNA ligase IV suppresses medulloblastoma formation. Cancer Res 62: 6395-6399
32. Lee A et al. (2005) Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 8: 723-729
33. Singh SK et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828
34. Singh SK et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401
35. Packer RJ et al. (2003) Medulloblastoma: Present concepts of stratification into risk groups. Pediatr Neurosurg 39: 60-67
36. Squire SE et al. (2006) Atypical teratoid/rhabdoid tumor: The controversy behind radiation therapy. J Neurooncol 81: 97-111
37. Rutkowski S (2006) Current treatment approaches to early childhood medulloblastoma. Expert Rev Neurother 6: 1211-1221
38. Evans AE et al. (1990) The treatment of medulloblastoma: Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72: 572-582
39. Tait DM et al. (1990) Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26: 464-469
40. Jenkin D et al. (2000) Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys 47: 573-584
41. Packer RJ et al. (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17: 2127-2136
42. Thomas PR et al. (2000) Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18: 3004-3011
43. Ris MD et al. (2001) Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol 19: 3470-3476
44. Packer RJ et al. (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24: 4202-4208
45. Mulhern RK et al. (2005) Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 23: 5511-5519
46. Zeltzer PM et al. (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17: 832-845
47. Packer RJ et al. (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81: 690-698
48. Gajjar A et al. (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Longterm results from a prospective, multicentre trial. Lancet Oncol 7 813-820
49. Verlooy J et al. (2006) Treatment of high risk medulloblastomas in children above the age of 3 years: A SFOP study. Eur J Cancer 42: 3004-3014
50. Burger PC et al. (2002) Surgical Pathology of the Nervous System and its Coverings. Philadelphia: Churchill Livingstone
51. Schofield D et al. (1995) Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Am J Pathol 146: 472-480
52. Pietsch T et al. (1997) Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 57: 2085-2088
53. Raffel C et al. (1997) Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57: 842-845
54. Sure U et al. (1995) Staging, scoring and grading of medulloblastoma: A postoperative prognosis predicting system based on the cases of a single institute. Acta Neurochir (Wien) 132: 59-65
55. Bailey CC et al. (1995) Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 25: 166-178
56. Giangaspero F et al. (1999) Medulloblastoma with extensive nodularity: A variant with favorable prognosis. J Neurosurg 91 971-977
57. Giangaspero F et al. (1992) Large-cell medulloblastomas: A distinct variant with highly aggressive behavior. Am J Surg Pathol 16: 687-693
58. Brown HG et al. (2000) "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59 857-865
59. Eberhart CG et al. (2002) Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94 552-560
60. McManamy CS et al. (2003) Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62: 627-632
61. Lamont JM et al. (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10: 5482-5493
62. Eberhart CG et al. (2003) Medulloblastomas with systemic metastases: Evaluation of tumor histopathology and clinical behavior in 23 patients. J Pediatr Hematol Oncol 25: 198-203
63. Eberhart CG and Burger PC (2003) Anaplasia and grading in medulloblastomas. Brain Pathol 13: 376-385
64. Leonard JR et al. (2001) Large cell/anaplastic medulloblastomas and medullomyoblastomas: Clinicopathological and genetic features. J Neurosurg 95: 82-88
65. Eberhart CG et al. (2002) Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/ anaplastic medulloblastomas. Brain Pathol 12: 36-44
66. Stearns D et al. (2006) c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 66: 673-681
67. Cogen PH et al. (1992) Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am J Hum Genet 50: 584-589
68. Batra SK et al. (1995) Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 24: 39-45
69. Pan E et al. (2005) Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 11: 4733-4740
70. Emadian SM et al. (1996) Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res 2: 1559-1564
71. Biegel JA et al. (1997) Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 3: 473-478
72. Taylor MD et al. (2000) Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: A review. Neurosurgery 47: 888-901
73. Rood BR et al. (2002) Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 62: 3794-3797
74. Di Marcotullio L et al. (2004) REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci USA 101: 10833-10838
75. Ferretti E et al. (2005) Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. Trends Mol Med 11: 537-545
76. Tomita T et al. (1988) Flow cytometric DNA analysis of medulloblastoma: Prognostic implication of aneuploidy. Cancer 61: 744-749
77. Yasue M et al. (1989) Prognostic importance of DNA ploidy in medulloblastoma of childhood. J Neurosurg 70: 385-391
78. Schofield DE et al. (1992) DNA content and other prognostic features in childhood medulloblastoma: Proposal of a scoring system. Cancer 69: 1307-1314
79. Gajjar AJ et al. (1993) Relation of tumor-cell ploidy to survival in children with medulloblastoma. J Clin Oncol 11: 2211-2217
80. Zerbini C et al. (1993) Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 11: 616-622
81. Carter SL et al. (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048
82. Scheurlen WG et al. (1998) Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16: 2478-2485
83. Aldosari N et al. (2002) MYCC and MYCN oncogene amplification in medulloblastoma: A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126: 540-544
84. Eberhart CG et al. (2004) Histopathological and molecular prognostic markers in medulloblastoma: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63: 441-449
85. Herms J et al. (2000) C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89: 395-402
86. Grotzer MA et al. (2001) MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/ medulloblastoma. Clin Cancer Res 7: 2425-2433
87. Gajjar A et al. (2004) Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22: 984-993
88. Gilbertson RJ et al. (1995) Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71: 473-477
89. Herms JW et al. (1997) Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 19: 510-515
90. Gilbertson R et al. (2001) Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85: 705-712
91. Hernan R et al. (2003) ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63: 140-148
92. Segal RA et al. (1994) Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 91: 12867-12871
93. Grotzer MA et al. (2000) TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18: 1027-1035
94. Kim JY et al. (1999) Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 59: 711-719
95. Ellison DW et al. (2005) beta-catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23: 7951-7957